NCRI has identified four scientific priority areas that need to be addressed to deliver better outcomes for all those affected…
Our year in numbers
0 NCRI Partners £ 0 m The amount spent by NCRI Partners on cancer research in the year 2019-20 0…
High-quality research development and delivery
At the core of NCRI’s activities is a focus on improving the quality and delivery of research to maximise patient…
Developing a research strategy for never smoker lung cancer patients
The NCRI Lung Group has identified lung cancer in never smokers as a critical area of focus and recently hosted…
NCRI Newsletter | May 2021
Yorkshire Cancer Research becomes NCRI Partner, Myeloma UK are hosting a public and patient involvement webinar and Brain Tumour Research…
Yorkshire Cancer Research becomes NCRI Partner
Yorkshire Cancer Research is the latest cancer research funder to join the NCRI Partnership. Yorkshire Cancer Research is an independent…
NCRI Newsletter | April 2021
NCRI’s Cellular Molecular Pathology Initiative (CMPath) is developing international consensus guidance on the inclusion of pathology in clinical trial protocols, SPIRIT-Path.…
Myeloma UK joins NCRI Partnership
The National Cancer Research Institute (NCRI) is delighted to announce that Myeloma UK, a UK cancer research charity focussing exclusively…
NCRI Newsletter | March 2021
Prioritising COVID-19 research questions and welcoming new NCRI Consumers.…
Can daily aspirin help to stop oesophageal cancer from coming back?
The NCRI Upper Gastrointestinal Group has published the following article outlining the Add-Asprin trial. We all know aspirin as a…
NCRI Newsletter | Feb 2021
Research updates from the NCRI LWBC and NCRI Brain Groups.…
Tribute to Professor Gordon McVie
It’s with great sadness that the NCRI joins the cancer research community in paying tribute to Professor Gordon McVie who…